0001004878-13-000176.txt : 20130611
0001004878-13-000176.hdr.sgml : 20130611
20130611172252
ACCESSION NUMBER: 0001004878-13-000176
CONFORMED SUBMISSION TYPE: DEFA14A
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20130611
DATE AS OF CHANGE: 20130611
EFFECTIVENESS DATE: 20130611
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: DEFA14A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11889
FILM NUMBER: 13906816
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
DEFA14A
1
defincorrespsmeetingjune-13.txt
LETTER SPECIAL MEETING VOTING
SCHEDULE 14A
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant [X]
Filed by Party other than the Registrant [ ]
Check the appropriate box:
[] Preliminary Proxy Statement
[] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
(2))
[] Definitive Proxy Statement
[X] Definitive Additional Materials
[] Soliciting Material Pursuant to ss.240.14a-12
CEL-SCI CORPORATION
(Name of Registrant as Specified In Its Charter)
William T. Hart - Attorney for Registrant
----------------------------------------
(Name of Person(s) Filing Proxy Statement)
Payment of Filing Fee (Check the appropriate box):
[] $500 per each party to the controversy pursuant to Exchange Act Rule 14a-6(i)
(3)
[] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
1) Title of each class of securities to which transaction applies:
2) Aggregate number of securities to which transaction applies:
3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11:
Dear Fellow Shareholder,
You recently received proxy materials in connection with the annual meeting of
shareholders of Cel-Sci Corporation to be held on June 25, 2013. According to
our latest records, your PROXY VOTE for this meeting HAS NOT YET BEEN RECEIVED.
The Company is asking shareholder to approve six proposals. Three of these
proposals, numbers 1, 2 and 6, are relatively routine in that they have been
part of the Annual Meeting agendas every year since 2000. Proposal number 3 is
to amend certain outdated portions of the company's articles of incorporation to
conform with the Colorado's Business Corporation Act.
The other two proposals, numbers 4 and 5, are extremely important to the
company's future. If we do not get 50% of all of the outstanding shares to vote
on proposals 4 and 5 they will fail and CEL-SCI's ability to structure the
financing of the Multikine Phase III clinical trial may be severely limited.
PLEASE VOTE IN FAVOR TODAY!
The Fourth Proposal concerns authorization granted by the shareholders to the
Company's Board of Directors to implement a proposed reverse stock split, IF the
Board determines it to be in the best interests of CEL-SCI's shareholders.
Shareholders gave this authorization to the Board of Directors in 2008 and 2009
and the Board elected not to proceed with a reverse split in those years. The
primary reason to give this authority to the Board of Directors again is to give
the Company more flexibility and options in the financing of the ongoing Phase 3
clinical trial.
The Fifth Proposal involves an increase in the Company's authorized
capitalization. The Company needs to increase its authorized shares of common
stock to accommodate the additional shares which may be issued if all
outstanding options, warrants and convertible securities were exercised or
converted and to allow the Company to raise additional capital through the sale
of common stock or securities convertible into common stock. If this proposal is
not approved, management's ability to finance the ongoing Phase III clinical
trial may be severely limited.
You can find more information on these proposals in the company's proxy
materials filed at: http://www.envisionreports.com/CVM.
The Board of Directors fully recommends a "FOR" vote on all six proposals.
Regardless of the number of shares you own, it is important that they be
represented at the annual shareholders meeting. Your vote matters to us and we
need your support.
YOUR BROKER WILL NOT VOTE YOUR SHARES IF THEY DON'T RECEIVE INSTRUCTIONS FROM
YOU. PLEASE VOTE YOUR SHARES NOW SO YOUR VOTE CAN BE COUNTED WITHOUT DELAY.
You still have time to vote by telephone or the internet. For telephone voting
please call the toll free number shown on the front of your voting instruction
form. To vote by internet please go to www.proxyvote.com. There is a control
number on the front of your voting instruction form. Please have the control
number ready when you call or log on and then follow the easy step-by-step
instructions.
YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!
2
If you have any questions relating to the shareholders meeting, voting your
shares, or need to request additional proxy materials, you may call our proxy
solicitation advisors Advantage Proxy toll-free at 1-877-870-8565 between the
hours of 9:00 a.m. and 9:00 p.m. Eastern Time, Monday through Friday.
We appreciate your support.
IF YOU HAVE RECENTLY MAILED YOUR PROXY OR CAST YOUR VOTE BY PHONE OR OVER THE
INTERNET, PLEASE ACCEPT OUR THANKS AND DISREGARD THIS REQUEST